Researchers have identified how and where in the genome a cancer chemotherapy agent acts on and "un-silences" the epigenetically silenced gene that causes Angelman syndrome, a rare neurodevelopmental ...
New research on the genetics of Prader-Willi and Angelman syndromes could help in developing personalised therapies for associated mental illness and autism features. Prader-Willi syndrome (PWS) and ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 19 (May 8, 2012), pp. 7403-7408 (6 pages) The Prader-Willi syndrome/Angelman syndrome (PWS/AS) imprinted ...
Recent data suggest that a chemotherapy agent used to treat metastatic cancers may also be therapeutic for Angelman or Prader-Willi syndrome, according to researchers. “What determines whether you ...
A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. The research, led by the Murdoch Children's ...
A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. A newly developed test to screen for three ...
Patients with duplication of the proximal long arm of chromosome 15 have been reported in several publications [1], and inv dup(15) which is used to define the psu dic(15;15) marker chromosomes is one ...
A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. The research, led by the Murdoch Children’s ...
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...
William Edberg smiles as he takes a a bite of his favorite meal, macaroni and cheese, on Saturday, Feb. 4, 2023, in his Rosemount, Minnesota, home. Born with Angelman syndrome, a rare neurogenetic ...
Soleno Therapeutics Inc. (NASDAQ: SLNO) pulled off in a major way its randomized-withdrawal phase III study with DCCR (diazoxide choline) in Prader-Willi syndrome, boosting the shares by $22.37, or ...
(SACRAMENTO, Calif.) -- UC Davis researchers have identified how and where in the genome a cancer chemotherapy agent acts on and 'un-silences' the epigenetically silenced gene that causes Angelman ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback